poisar

Stocks · News reference

IDEAYA Biosciences Q2 EPS $(1.22) Misses $(1.09) Estimate, Sales $8.857M Beat $5.015M Estimate

Aug 4, 2026, 10:11 AMBenzinga Newsdesk

IDEAYA Biosciences (NASDAQ:IDYA) reported quarterly losses of $(1.22) per share which missed the analyst consensus estimate of $(1.09) by 11.93 percent. This is a 38.64 percent decrease over losses of $(0.88) per share

Read original sourceMore stocks news

Reference details

Connected markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

IDYA
Source
benzinga
Observed
Aug 4, 2026, 10:11 AM
Checked
Aug 4, 2026, 10:11 AM
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading

  1. Aug 19, 2026, 10:03 AMBenzinga Newsdesk

    IDEAYA Biosciences Enters Clinical Collaboration With Roche's Genentech To Evaluate The Efficacy And Safety Of IDE892, Its Investigational MTA-Cooperative PRMT5 Inhibitor, In Combination With GDC-7035, Genentech's KRAS G12D Inhibitor, In Patients With Pancreatic Ductal Adenocarcinoma

    Collaboration to to evaluate the efficacy and safety of IDE892, its investigational, potential best-in-class MTA-cooperative PRMT5 inhibitor, in combination with GDC-7035 (RG6620), Genentech's KRAS G12D inhibitor,

    Read original at benzinga
    IDYARHHBY